Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study
This is the first study to show that a calcimimetic improves serum P and cCa control without inducing severe hypocalcemia in patients with iPTH levels ≤300 pg/mL. Upacicalcet is efficacious in HD patients with mild-to-severe SHPT, with few safety concerns.
Authors
- Takayuki Hamano (ORCID: https://orcid.org/0000-0002-2100-9106)
- Yoshitaka Isaka (ORCID: https://orcid.org/0000-0002-0820-7167)
- Keitaro Yokoyama (ORCID: https://orcid.org/0000-0002-6122-592X)
- Tadao Akizawa (ORCID: https://orcid.org/0000-0002-6150-9201)
- Fumihiko Koiwa (ORCID: https://orcid.org/0000-0003-3832-701X)
- Daisuke Honda (ORCID: https://orcid.org/0000-0001-5624-7553)
- Yukihisa S. Watanabe (ORCID: https://orcid.org/0000-0001-9154-0915)
- Masafumi Fukagawa (ORCID: https://orcid.org/0000-0002-7832-2339)
- Yosuke Inagaki
Institutions
- Osaka Gakuin University (JP)
- Jikei University School of Medicine (JP)
- SHOWA Medical University (JP)
- Tokai University (JP)
- Nagoya City University (JP)
- Riso Kagaku (Japan) (JP)
- SHOWA Medical University Fujigaoka Hospital (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- American Journal of Nephrology
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1159/000541493
- Citations
- 2
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.68